

Rajasthan Medical Services Corporation Limited

Gandhi Block, SwasthyaBhawan, Tilak Marg, C-Scheme, Jaipur-302005 (Raj.)

Phone No: 0141-2228066, 2228064 Fax No. 0141-2228065 Website: <http://rmsc.health.rajasthan.gov.in>

CIN:U24232RJ2011SGC035067

E_mail :edprmsc@nic.in

Ref. No.:- F.02(363)/RMSCL/PROCUREMENT /DRUG/ NIB-16/2022/8517

Dated:- 14/11/2022

Corrigendum - I

Subject:- Amendments in Bid conditions, Item specifications and Extension in Date.

Ref.:- Pre bid meeting dated 10.11.2022 and NIB No. F.02(363)/RMSCL/PROCUREMENT /DRUG/

NIB-16/2022/8359 Dated:-04.11.2022

S. No	Read as Extended Date / Amended Condition / Technical Specification/ Packing Unit/ Shelf Life													
1.	Date Extended for submission of E-bids reference F.02(363)/RMSCL/PROCUREMENT/DRUG/NIB-16/2022/8359 Dated:-04.11.2022 is as below:-													
	Last date and time of submission of online bids	29.11.2022 at 6.00 PM												
	Bid security, Tender fees, RISL fees and Empanelment fees through challan and Physically	29.11.2022 at 6.00 PM												
	Date and time of opening of Online technical bids	30.11.2022 at 11.00 AM												
2.	Annexure - VIII (List of Drugs with Specifications) and BoQ	Annexure - VIII (List of Drugs with Specifications) and BoQ												
	<table border="1"> <thead> <tr> <th>Code No.</th> <th>Name of Drug with specification</th> <th>Packing unit</th> </tr> </thead> <tbody> <tr> <td>NRD-457</td> <td>Nevirapine 200mg. Each tablet contain Nevirapine 200mg</td> <td>10x10 Tab</td> </tr> </tbody> </table>	Code No.	Name of Drug with specification	Packing unit	NRD-457	Nevirapine 200mg. Each tablet contain Nevirapine 200mg	10x10 Tab	<table border="1"> <thead> <tr> <th>Code No.</th> <th>Name of Drug with specification</th> <th>Amended Packing Unit</th> </tr> </thead> <tbody> <tr> <td>NRD-457</td> <td>Nevirapine 200mg. Each tablet contain Nevirapine 200mg</td> <td>10x10 Tab/ 60 Tab (Rate should be quoted for 100 tablet)</td> </tr> </tbody> </table>	Code No.	Name of Drug with specification	Amended Packing Unit	NRD-457	Nevirapine 200mg. Each tablet contain Nevirapine 200mg	10x10 Tab/ 60 Tab (Rate should be quoted for 100 tablet)
Code No.	Name of Drug with specification	Packing unit												
NRD-457	Nevirapine 200mg. Each tablet contain Nevirapine 200mg	10x10 Tab												
Code No.	Name of Drug with specification	Amended Packing Unit												
NRD-457	Nevirapine 200mg. Each tablet contain Nevirapine 200mg	10x10 Tab/ 60 Tab (Rate should be quoted for 100 tablet)												
3.	Annexure - VIII (List of Drugs with Specifications) and BoQ	Annexure - VIII (List of Drugs with Specifications) and BoQ												
	<table border="1"> <thead> <tr> <th>Code No.</th> <th>Name of Drug with specification</th> <th>Minimum labelled Shelf Life (In Months)</th> </tr> </thead> <tbody> <tr> <td>NRD-72</td> <td>Minocycline 50mg Capsule</td> <td>24</td> </tr> </tbody> </table>	Code No.	Name of Drug with specification	Minimum labelled Shelf Life (In Months)	NRD-72	Minocycline 50mg Capsule	24	<table border="1"> <thead> <tr> <th>Code No.</th> <th>Name of Drug with specification</th> <th>Minimum labelled Shelf Life (In Months)</th> </tr> </thead> <tbody> <tr> <td>NRD-72</td> <td>Minocycline 50mg Capsule</td> <td>18</td> </tr> </tbody> </table>	Code No.	Name of Drug with specification	Minimum labelled Shelf Life (In Months)	NRD-72	Minocycline 50mg Capsule	18
Code No.	Name of Drug with specification	Minimum labelled Shelf Life (In Months)												
NRD-72	Minocycline 50mg Capsule	24												
Code No.	Name of Drug with specification	Minimum labelled Shelf Life (In Months)												
NRD-72	Minocycline 50mg Capsule	18												
4.	Annexure - VIII (List of Drugs with Specifications) and BoQ	Annexure - VIII (List of Drugs with Specifications) and BoQ												
	<table border="1"> <thead> <tr> <th>Code No.</th> <th>Name of Drug with specification</th> </tr> </thead> <tbody> <tr> <td>NRD-887</td> <td>Ethiodized oil (Lipiodol) Inj.</td> </tr> </tbody> </table>	Code No.	Name of Drug with specification	NRD-887	Ethiodized oil (Lipiodol) Inj.	<table border="1"> <thead> <tr> <th>Code No.</th> <th>Name of Drug with specification</th> </tr> </thead> <tbody> <tr> <td>NRD-887</td> <td>Ethiodized oil Inj.</td> </tr> </tbody> </table>	Code No.	Name of Drug with specification	NRD-887	Ethiodized oil Inj.				
Code No.	Name of Drug with specification													
NRD-887	Ethiodized oil (Lipiodol) Inj.													
Code No.	Name of Drug with specification													
NRD-887	Ethiodized oil Inj.													
5.	<p>Clause 2(c) ELIGIBILITY CRITERIA Clause 5 (i) (j) TECHNICAL BID (c)Bidder should have at least 3 years market standing as a manufacturer for the items quoted in the bid, on the date of bid opening. In the case of imported products, the product should have minimum 3 years standing in the market. The</p>	<p>Clause 2(c) ELIGIBILITY CRITERIA Clause 5 (i) (j) TECHNICAL BID (c)Bidder should have at least 3 years market standing as a manufacturer for the items quoted in the bid, on the date of bid opening. In the case of imported products, the product should have minimum 3 years standing in the market. The</p>												



S. No	Read as Extended Date / Amended Condition / Technical Specification/ Packing Unit/ Shelf Life										
	<p>importer should have at least 3 year standing as manufacturer/ importer of drugs in general. Imported drugs shall be accepted in brand name also. <u>The period of Market Standing will be reckoned from the date of issue of Product Permission.</u></p> <p>importer should have at least 3 year standing as manufacturer/ importer of drugs in general. Imported drugs shall be accepted in brand name also. <u>The period of Market Standing will be reckoned from the date of issue of Product Permission.</u></p> <table border="1" data-bbox="816 508 1332 840"> <thead> <tr> <th>Code No.</th> <th>Relaxation in Condition of Market Standing Certificate</th> </tr> </thead> <tbody> <tr> <td>NRD-846</td> <td>Market Standing Certificate of one year accepted.</td> </tr> <tr> <td>NRD-849</td> <td>Market Standing Certificate of one year accepted.</td> </tr> <tr> <td>NRD-860</td> <td>Market Standing Certificate of one year accepted.</td> </tr> <tr> <td>NRD-887</td> <td>Market Standing Certificate of Six Months accepted.</td> </tr> </tbody> </table> <p>For item code NRD-846, NRD-849, NRD-860 & NRD-887 if copy of Market standing certificate has not been submitted in main bid then copy of application for Market Standing Certificate issue should be enclosed without which bid will be rejected. The copy of Market Standing Certificate should be submitted later by the last date of submission to clarification letter issued by the RMSCL. No replies would be entertained after last date of reply submission to clarification letters issued by the RMSCL.</p>	Code No.	Relaxation in Condition of Market Standing Certificate	NRD-846	Market Standing Certificate of one year accepted.	NRD-849	Market Standing Certificate of one year accepted.	NRD-860	Market Standing Certificate of one year accepted.	NRD-887	Market Standing Certificate of Six Months accepted.
Code No.	Relaxation in Condition of Market Standing Certificate										
NRD-846	Market Standing Certificate of one year accepted.										
NRD-849	Market Standing Certificate of one year accepted.										
NRD-860	Market Standing Certificate of one year accepted.										
NRD-887	Market Standing Certificate of Six Months accepted.										
6.	<p>Annexure-VIII and BOQ:-</p> <p>Item code no NRD-168, NRD-248, NRD-405, NRD-455, NRD-840, NRD-841, NRD-842, NRD-843, NRD-844 and NRD-845 are deleted from the bid.</p> <p><u>(Total drugs items in the bid are now 90)</u></p>										

Note:-

- It may be noted that if any further amendments are issued then a corrigendum will be published and informed.
- Rest of the terms and conditions will remain the same.


 Executive Director (Proc.)
 RMSCL